ZAM | Jotup

Historic Milestone: UK Patients Receive First CannEpil® Delivery through 'I AM Billy Foundation' and GMC Specialist Register

Retrieved on:

Wednesday, May 31, 2023

Epilepsy, GMC, LSE, General Medical Council, MXC, IMP, ZAM, ASX, Research, MGC, Hemispherectomy, Parkinson's disease, Patient, OTC, United Kingdom, NHS, Chronic pain, Pharmaceutical industry

LONDON, May 31, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received by its first patients in the United Kingdom.

Key Points:

It is part of MGC's rigorous clinical development programme for patients suffering from refractory epilepsy, also known as drug-resistant epilepsy.
The initiative permits clinicians listed on The General Medical Council (GMC) specialist register to prescribe CannEpil®.
The delivery also supports the RESCAS study, a research initiative aiming to address the substantial unmet medical need of refractory epilepsy.
CannEpil® was supplied to the 'I AM Billy Foundation' through the NHS's Refractory Epilepsy Specialist Clinical Advisory Service, the only route in the UK for patients to receive public funding for cannabis-based treatments of refractory epilepsy.

Pervasip Announces Strategic Acquistion and $4 Million in New Revenues

Retrieved on:

Monday, October 10, 2022

Emerald, News, Time, ZAM, Cannabinol, LOI, Perception, Biomass, PVSP, Company, Acquisition, Legislation, Intention, Washington State, Letter, Zen, Psilocybin, GLOBE, OTC, Â, Security (finance), Retail, Risk management, DABCO

BCCTGs brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory.

Key Points:

BCCTGs brands, which generate $4 million in annualized revenues, manufactured in a state-of-the-art laboratory.
In addition, Pervasip will provide a group of BCCTG owners, investors and employees 10.2% of Pervasips fully diluted equity in the form of restricted preferred stock.
We are excited to add the BCCTG team to our Washington operation and fill critical open positions with market leading expertise.
Pervasip beneficially owns 10 million shares of common stock of KRTL Holding Group Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin.

Restructuring Leading to $500,000 in Annual Cost Savings Plus New Customer Contracts

Retrieved on:

Thursday, August 4, 2022

Legislation, GLOBE, PVSP, Biomass, Cannabinol, Psilocybin, Perception, Letter, Company, ZAM, OTC, Intention, News, Risk management

The ZAM management team has continued to aggressively restructure various aspects of the business, from real estate to cultivation operations.

Key Points:

The ZAM management team has continued to aggressively restructure various aspects of the business, from real estate to cultivation operations.
The last 60 days have seen several such changes which are adding upwards of $500,000 in annual direct positive contribution to its bottom line.
For all cannabis connoisseurs all that needs to be said about that brand is IYKYK (bestselling small batch top shelf brand).
Several similar arrangements will be announced soon, following through on one of the other major initiatives outlined in the January 2022 Shareholder letter.

New Partnership is Adding Up to $12 Million in Concentrates Revenue

Retrieved on:

Wednesday, July 13, 2022

LLC, Perception, News, Cannabinol, Intention, ZAM, Biomass, Company, Partnership, OTC, Psilocybin, GLOBE, PVSP, Legislation, Retail, Risk management, Washington State

The $380 million-dollar annual Washington State vape and concentrates market is an untapped opportunity for Artizen.

Key Points:

The $380 million-dollar annual Washington State vape and concentrates market is an untapped opportunity for Artizen.
The Dabs4Less and Vapes4Less brands are already established in several retail stores across the state of Washington generating roughly $200,000.
Priced for sell through and taking advantage of certain production efficiencies the brand is expected to drive sales of up to $700,000 per month or $8.4 million annually.
Additional vape and concentrates brands and offerings will be developed by this new partnership and rolled out during the third and fourth quarter of 2022, driving annualized revenues towards $12 million for Artizens vape and concentrates vertical.

Pervasip Teams with Premier Cultivation Group to Generate an Additional $5 Million Annually Over the Next 24 Months

Retrieved on:

Tuesday, March 29, 2022

Company, Growth, Legislation, Genetics, Cannabinol, Perception, ZAM, CEO, FSA, Biomass, Intention, SOP, GLOBE, Psilocybin, News, OTC, PVSP, Partnership, Drug, Risk management

The FSA team brings years of experience in some of the most recognized cultivation environments and with some of the most well known cannabis brands.

Key Points:

The FSA team brings years of experience in some of the most recognized cultivation environments and with some of the most well known cannabis brands.
ZAMs existing clients operate four licensed cannabis cultivation and one processing facility in Washington.
Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin.
Further, any forward-looking information speaks only as of the date on which such statement is made.

PERVASIP ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2021

Retrieved on:

Tuesday, March 1, 2022

Seattle, WA , March 01, 2022 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (Pervasip or the Company), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its fiscal years ended November 30, 2021, and November 30, 2020.

Key Points:

Seattle, WA , March 01, 2022 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (Pervasip or the Company), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its fiscal years ended November 30, 2021, and November 30, 2020.
The Company acquired Artizen Corporation and its operating subsidiary, Zen Asset Management LLC (ZAM), effective September 1, 2021.
Artizen and ZAM improved on those results with about $17.1 million in revenue and about $530,000 in net income attributable to Pervasips shareholders for the year ended November 30, 2021.
Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin.

Pervasip Announces 330% Growth in Wholesale Division

Retrieved on:

Tuesday, January 18, 2022

News, Intention, Psilocybin, Legislation, Perception, Growth, Cannabinol, PVSP, ZAM, OTC Markets Group, Michael Burtscher, Industry, Biomass, Company, Risk management

As Pervasip recently announced, several exciting accomplishments and initiatives will be shared over the next few months, and wholesale growth is one of the keystone initiatives that has been successfully executed over the past months.

Key Points:

As Pervasip recently announced, several exciting accomplishments and initiatives will be shared over the next few months, and wholesale growth is one of the keystone initiatives that has been successfully executed over the past months.
Pervasip's newly created wholesale division is poised for continuing growth in 2022, and has become an important go to market channel for various independent cultivation partners that the Pervasip group of companies is servicing.
We are turning this opportunity into a wholesale market, managed by our wholesale group where buyers and sellers can easily exchange inventory information and execute purchases."
Burtscher continued: "We estimate growth in the new wholesale division will reach $12 million in annualized revenues within a year.

Pervasip Raises $2.5 Million in Non-Dilutive Capital

Retrieved on:

Thursday, January 13, 2022

Pervasip management estimates the additional output to be initially valued at about $6 million in annualized revenues, with pre-tax operating income margins exceeding 10%.

Key Points:

Pervasip management estimates the additional output to be initially valued at about $6 million in annualized revenues, with pre-tax operating income margins exceeding 10%.
We cannot think of a better group than ZAM to partner with and realize their next phase of development for this asset.
"The $2.5 million in capital will be complemented by $1.5 million in equipment leasing and another $1 million in garden equipment already owned by ZAM," said George Jordan, Pervasip's Chief Financial Officer.
Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin.

Zen Asset Management Finalizing Strategic Cultivation Changes

Retrieved on:

Tuesday, January 11, 2022

SOP, News, Intention, Psilocybin, Legislation, Perception, Cannabis, Cannabinol, Flower, PVSP, ZAM, OTC Markets Group, Industry, Biomass, Company, Risk management, Washington State

Seattle, Washington--(Newsfile Corp. - January 11, 2022) - Pervasip Corp. (OTC Pink: PVSP) ("Pervasip" or the "Company"), a developer of companies and technologies in high value emerging markets, and its subsidiaries, Artizen Corporation ("Artizen") and Zen Asset Management LLC ("ZAM"), a diversified asset management company that was founded to acquire, develop, and support companies and technologies in the cannabis industry, have finalized a strategic plan to upgrade all Washington State cultivation facilities and garden management.

Key Points:

Seattle, Washington--(Newsfile Corp. - January 11, 2022) - Pervasip Corp. (OTC Pink: PVSP) ("Pervasip" or the "Company"), a developer of companies and technologies in high value emerging markets, and its subsidiaries, Artizen Corporation ("Artizen") and Zen Asset Management LLC ("ZAM"), a diversified asset management company that was founded to acquire, develop, and support companies and technologies in the cannabis industry, have finalized a strategic plan to upgrade all Washington State cultivation facilities and garden management.
We are proud to have built a strong network of partners which will work with us side by side on executing these strategic initiatives.
Pervasip Corp., a developer of companies and technologies in high value emerging markets, owns Artizen Corporation and its subsidiary, Zen Asset Management LLC, a diversified asset management company founded to acquire, develop, and support companies and technologies in the cannabis industry.
ZAM's existing clients operate four licensed cannabis cultivation and one processing facility in Washington.

Pervasip Appoints New CFO and COO

Retrieved on:

Thursday, January 6, 2022

German Burtscher, Pervasip's President & CEO, said, "I am extremely excited by the appointment of George as our new CFO & COO.

Key Points:

German Burtscher, Pervasip's President & CEO, said, "I am extremely excited by the appointment of George as our new CFO & COO.
As a cofounder of Artizen Cannabis Company and ZAM he has led various operational and financial aspects in the development of several cultivation facilities.
"I'm personally thrilled to accept this appointment," added George Jordan, the Company's new CFO & COO.
Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin.